# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Illumina welcomes the European Court of Justice ruling that the European Commission lacked jurisdiction over its acquisition of...
Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Ju...
Argus Research analyst Jasper Hellweg upgrades Illumina (NASDAQ:ILMN) from Hold to Buy and announces $150 price target.
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-ca...